This study ia evaluating the safety and efficacy of the study drug seladelpar in people with Primary Biliary Cholangitis (PBC) and abnormal liver function. This will be done by looking at how the study drug seladelpar affects PBC and observing changes in the laboratory tests that are used to monitor the severity of PBC and its prognosis.

PBC is a chronic disease of the liver resulting from progressive destruction of bile ducts in the liver. Bile is a substance produced by the liver to facilitate digestion. With PBC, the bile ducts develop inflammation and causes liver damage, which may eventually lead to cirrhosis (liver scarring).

Seladelpar is being developed to reduce PBC and is considered to be experimental/investigational, meaning it is not approved by the U.S. Food and Drug Administration (FDA).

All study participants will receive 10 mg tablets of seladelpar.

Participation in this study will last for up to 12 weeks and participants will be compensated for their time.